{"prompt": "['4.5.4', 'Vital Signs', 'Vital signs will include measurement of body temperature (oral, rectal, axillary, or tympanic),', 'heart and respiratory rates, temperature (oral, rectal, axillary, or tympanic), systolic and', 'diastolio-blood pressures, hoight, and weight, and should be measured recorded. On treatment', 'days, measurement should occur prior to emicizumab administration. before-study drug', 'administration. Height will be only measured at selected visits. Frequency of Additional vital sign', 'assessments should follow the Schedule of Activities (Appendix 1', 'Schedule of Activities', '>but may also be taken anytime as unscheduled assessments as judged by the investigator.', 'In addition, vital signs may be taken to help monitor for hypersensitivity reactions during or', \"after injections at the investigator's discretion, although these data should not be entered\", 'into the eCRF.', '4.5.5', 'Concomitant Medications', 'The definition of concomitant medications, as well as permitted and prohibited medications is', 'described in Section 4.4. Concomitant medications used by a patient from 4 weeks prior to', 'initiation of emicizumab to the Study Completion/Early Termination Visit (or the Safety', 'Follow-up Visit, if applicable) should be reported to the investigator and recorded on the', 'Concomitant Medications eCRF.', 'Any hemostatic medications (e.g. bypassing agents) and other medications used to treat or prevent', 'bleeds in the 6-month period prior to starting emicizumab treatment will also be collected. Treatments', 'for bleeds (i.e., bypassing agents and other medications to treat bleeds), will be collected in the bleed', 'records.', '4.5.6', 'Laboratory, Biomarker, and Other Biological Samples', 'Central laboratory assessments will be performed as indicated (see Table 9) in the Schodule', 'of Activities (Appendix 1', 'Schedule of Activities', \"7. Unless otherwise specified, additional analysis may be performed as per the investigator's\", \"discretion at a local laboratory, as per the investigator's discretion. Any additional laboratory\", \"results which are required as part of the patient's safety assessment should be recorded in the\", 'unscheduled visit eCRFs. Central labs are part of the non-eCCF data which will be sent to the', 'Sponsor directly by the central lab vendor.', 'On treatment days, the days of study drug administration, blood collection should occur', 'within 2 hours prior to emicizumab administration unless otherwise specified. -laboratory', 'samples should be drawn before the administration of the study drug.', 'Table 9', 'Central vs Local Laboratory Assessments', 'Sample', 'Laboratory', 'Hematology and blood chemistry', 'Central', 'Emicizumab - F. Hoffmann-La Roche Ltd', '30 / Protocol MO39129, Version 3']['Sample', 'Laboratory', 'Pregnancy tests', 'Local', 'HIV and hepatitis serology', 'Local', 'Anti-FVIII antibodies', 'Central', 'Anti-emicizumab antibodies', 'Central', 'Pharmacokinetic samples', 'Central', 'Safety biomarkers', 'Central', 'Safety coagulation system biomarkers', 'Central', 'PD biomarkers', 'Central', 'Bone and joint biomarkers', 'Central', 'Extra testing with use of bypass agents', 'Central', '4.5.6.1', 'Hematology and Blood Chemistry', 'Hematology and blood chemistry tests include: Samples for the following laboratory tests will be', 'sent to the central laboratory for analysis:', 'Serum chemistry (sodium, potassium, chloride, glucose, blood urea nitrogen (BUN),', 'creatinine, calcium, phosphorus, magnesium, total and direct bilirubin, total protein,', 'albumin, ALT, AST, lactate dehydrogenase (LDH), alkaline phosphatase, and creatine', 'phosphokinase)', 'Laboratory assessments completed during Screening do not have to be repeated at Week 1, if the', \"period between Screening and Week 1 is < 5 days and there has been no change in the patient's health\", 'status as assessed by the investigator.', 'Samples will be sent to the central laboratory for analysis.', '4.5.6.2', 'Pregnancy Tests', 'Female patients of childbearing potential (including those who have had a tubal ligation) will be', 'required to have a negative serum pregnancy test result during Screening, and again within 7 days', 'prior to the first dose of emicizumab. Urine pregnancy tests will be performed throughout the study', 'treatment period. Pregnancy testing will be conducted at the local laboratory.', '4.5.6.3', 'HIV and Hepatitis Serology', 'The specific tests utilized for hepatitis and HIV testing are per local standard of care. As this patient', 'population is at high risk for HIV, hepatitis A, B and C, sites should consider testing for these. While', 'the specific serological tests used is at the discretion of the Investigator, this is with the understanding', \"that the status of that participants' hepatitis or HIV is confidently known at time at enrollment. HIV\", 'and hepatitis serology tests will be conducted at the local laboratory.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '31 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}